Applications of Physiologically-Based Pharmacokinetic (PBPK) Modeling

Dear Colleagues,

Physiologically-based pharmacokinetic (PBPK) modeling has matured to a powerful and widely accepted approach to integrate information from different stages of drug research and development, to predict untested scenarios and to support decision making. The three major regulatory agencies (FDA, EMA, and PMDA) encourage PBPK modeling for the assessment of drug-drug interaction (DDI) potential, the development of alternative dosing regimens or even to waive clinical studies. Furthermore, PBPK models are increasingly used to evaluate the effects of patient factors on drug exposure, and they are excellent tools to develop alternative dosing regimens for patients.

This Special Issue is dedicated to new, cutting-edge examples of the application of PBPK modeling, to show its versatility and to highlight recent advances in the field. Modeling scientists are cordially invited to share their research covering the full spectrum of PBPK modeling and simulation, including (but not limited to) the pharmacokinetics of special populations (e.g. geriatrics, pediatrics, pregnancy, ICU), modeling of pathophysiology (e.g. renal impairment, hepatic impairment), drug-gene interactions, drug-drug interactions, integration of tissue concentration (e.g. by imaging techniques), PBPK covariate modeling, PBPK-based precision dosing, PBPK/PD modeling, PBPK-based Quantitative Systems Pharmacology (QSP) approaches or technical advances.

Prof. Dr. Thorsten Lehr
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.